AlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approachbroad
AlkaBurst2.0 · Horizon Europe grant · 2022-11-01–2025-07-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATORCHALLENGES-01. CORDIS record →
Objective
Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way. Our core technology combines our disruptive patented automated bioreactor-AlkaBurst2.0 with unique knowhow on gene expression methods, culture media and extraction. Our process offers high productivity and a low carbon footprint.The pharma industry is carbon intensive with recurring problems of quality & safety. Moreover, many critical APIs are outsourced to Asia to cut costs. AlkaBurst2.0 allows a local standardised production of safe & clean APIs in its automated process saving 75% time, 80% space, 95% electricity, 98% water.We first validated the production for Covid-19 natural vaccine adjuvants QS21/7, cannabinoids & certain recombinant proteins for the urgent market demand. We need 7.5M to build & validate our pilot and expect to generate 125M revenue by 2028 with 105 job
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ALKION BIOINNOVATIONS | FR | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.